Eagle Pharmaceuticals Statistics
Eagle Pharmaceuticals (EGRX) Stock Statistics & Valuation Metrics
Total Valuation
Eagle Pharmaceuticals has a market cap or net worth of $11.72M. The enterprise value is $312.83M.
- Market Cap
- $11.72M
- Enterprise Value
- $312.83M
Share Statistics
Eagle Pharmaceuticals has 13,023,123 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,023,123
- Owned by Insiders
- ―
- Owned by Institutions
- 0.64%
Financial Efficiency
Eagle Pharmaceuticals’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 15.51%.
- Return on Equity (ROE)
- 0.15
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 15.51%
- Return on Capital Employed (ROCE)
- 0.27
- Revenue Per Employee
- 2.35M
- Profits Per Employee
- 264.01K
- Employee Count
- 135
- Asset Turnover
- 0.78
- Inventory Turnover
- 1.99
Valuation Ratios
The current PE Ratio of Eagle Pharmaceuticals is 0.09. Eagle Pharmaceuticals’s PEG ratio is -0.00.
- PE Ratio
- 0.09
- PS Ratio
- 0.01
- PB Ratio
- 0.01
- Price to FCF
- 0.07
- Price to Operating Cash Flow
- 0.06
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Eagle Pharmaceuticals had revenue of 316.61M and earned 35.64M in profits. Earnings per share was 2.76.
- Revenue
- 316.61M
- Gross Profit
- 221.67M
- Operating Income
- 80.96M
- Pretax Income
- 61.43M
- Net Income
- 35.64M
- EBITDA
- 77.50M
- Earnings Per Share (EPS)
- 2.76
Cash Flow
In the last 12 months, operating cash flow was -9.32M and capital expenditures -74,000, giving a free cash flow of -9.39M billion.
- Operating Cash Flow
- -9.32M
- Free Cash Flow
- -9.39M
- Free Cash Flow per Share
- 3.91
Dividends & Yields
Eagle Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1535.94%
- Earnings Yield
- 1102.28%
Stock Price Statistics
- Beta
- -4.43
- 52-Week Price Change
- 18.42%
- 50-Day Moving Average
- 1.00
- 200-Day Moving Average
- 0.56
- Relative Strength Index (RSI)
- 47.71
- Average Volume (3m)
- 4,294
Important Dates
Eagle Pharmaceuticals upcoming earnings date is May 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- May 11, 2026
- Next Earnings Date
- May 10, 2027
- Ex-Dividend Date
- ―
Financial Position
Eagle Pharmaceuticals as a current ratio of 1.70, with Debt / Equity ratio of 29.02%
- Current Ratio
- 1.70
- Quick Ratio
- 1.27
- Debt to Market Cap
- 0.17
- Net Debt to EBITDA
- 0.16
- Interest Coverage Ratio
- 20.01
Taxes
In the past 12 months, Eagle Pharmaceuticals has paid 25.79M in taxes.
- Income Tax
- 25.79M
- Effective Tax Rate
- 0.42
Enterprise Valuation
Eagle Pharmaceuticals EV to EBITDA ratio is 0.20, with an EV/FCF ratio of 0.31.
- EV to Sales
- 0.05
- EV to EBITDA
- 0.20
- EV to Free Cash Flow
- 0.31
- EV to Operating Cash Flow
- 0.31
Balance Sheet
Eagle Pharmaceuticals has $15.35M in cash and marketable securities with $71.61M in debt, giving a net cash position of -$56.26M billion.
- Cash & Marketable Securities
- $15.35M
- Total Debt
- $71.61M
- Net Cash
- -$56.26M
- Net Cash Per Share
- -$4.32
- Tangible Book Value Per Share
- $7.61
Margins
Gross margin is 70.01%, with operating margin of 25.57%, and net profit margin of 11.26%.
- Gross Margin
- 70.01%
- Operating Margin
- 25.57%
- Pretax Margin
- 19.40%
- Net Profit Margin
- 11.26%
- EBITDA Margin
- 24.48%
- EBIT Margin
- 20.68%
